Abstract:Introduction: Although metastatic breast cancer is the second leading cause of cancer death in women, the genomic findings in metastatic breast cancer are not as well characterized as those of primary breast cancers. Metastatic tumors are genetically heterogenous, enriched for resistance mutations, and often lack targetable alterations. Improved understanding of the molecular mechanisms that drive metastatic disease of all receptor subtypes is required to identify possible molecular targets and to develop new targeted therapies in an effort to reduce the mortality. Methods: A cohort of 50 metastatic breast cancer cases (n=33 ER+/PR+, n=3 ER+/HER2+, n=3 ER-/HER2+ n=11 TNBC) sequenced at our medical center between 2018-2023 was evaluated, and the molecular findings of the major subtypes were analyzed. Genomic data included mutations, copy number alterations, tumor mutation burden and microsatellite instability. Results: The most frequent somatic alteration were PIK3CA mutations, involving 17/33 of ER+/PR+/HER- tumors, 5/11 TNBC tumors and 5/6 HER+ cases. TP53 mutations (frameshift and missense) were more frequently identified in TNBC and HER2+ cases (p 0.05). ESR1 mutations involved 15% of the ER positive cancers and were frequently associated with co-occurring CCND1 and FGFR1 copy number gains. Significant genomic losses that drive tumorigenesis were also detected. Both CDKN2a and PTEN deletions were found in ER/PR positive disease, as well as triple negative tumors. Genomic deletions associated with worse outcomes such as TP53 and DICER1 were also detected. ERBB2 amplification was 100% concordant with our immunohistochemical and FISH results for the 6 HER2 positive cases. All 50 cases demonstrated a low tumor mutation burden and were microsatellite stable. Conclusion: We detected driver alterations that involve multiple pathways including estrogen receptor signaling, PI3K/AKT/MTOR, the cell cycle, and receptor tyrosine kinases. The genomic alterations are enriched for resistance mechanisms, like ESR1 mutations and FGFR1 gains that mediate resistance to endocrine treatment, as well as PIK3CA, also implicated in both endocrine and HER2-targeting therapy resistance. Of particular interest, were the amplifications detected in the ER+/PR+ tumors, such as CCND1 on chromosome 11q, FGFR1 on 8p and MYC on 8q, which were detected in almost half (45%) of our hormone receptor positive cohort. Some of the identified driver amplifications also define a subset of the Integrated Molecular Subtypes (Curtis et al., Nature; 486(7403): 346–352), i.e., Clusters 2, 6 and 9 that are typically hormone receptor positive but associated with either a very poor prognosis (Cluster 2) or an intermediate prognosis (Clusters 6 and 9), unlike the copy neutral ER positive tumors or those with the classic 1p and 16q alterations. Therefore, copy number profiling of advanced-stage breast cancers may be a useful tool for determining prognosis, identifying possible targetable driver pathways and selecting appropriate patients for molecularly guided clinical trials. Citation Format: Kimberly Cole, Melissa Tjota, Jeremy Segal, Peng Wang, Susanne Crespo-Ramos. Genomic findings in metastatic breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO5-24-06.

Select gene mutations associated with survival outcomes in ER‐positive ERBB2‐negative early‐stage invasive breast cancer: A single‐institutional tissue bank study

Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer

Association of Pathway Mutations With Survival in Taiwanese Breast Cancers

Abstract PO3-08-10: Somatic Mutations of a Multigene Panel in Chinese HER2-positive Patients Undergoing Neoadjuvant Therapy and Impact on Prognosis Based on TP53 Status:A Single-Institution Retrospective Cohort

Abstract PO5-24-06: Genomic findings in metastatic breast cancer

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer

Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer

Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients

Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients

261 BRCA1/2 Mutations Predict Better Survival in High-Grade Endometrioid Endometrial Cancer

P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

Identification of Breast Cancer Subtypes Based on Endoplasmic Reticulum Stress-Related Genes and Analysis of Prognosis and Immune Microenvironment in Breast Cancer Patients

Genetic analysis of cervical cancer with lymph node metastasis

Abstract 4333: High Incidence of ERBB2 Amplification Associated with Microsatellite Stable Status in Chinese Colorectal Cancer Patients

Impact of Pathogenic Germline BRCA1/2 and PALB2 Mutations and Tumor Aneuploidy in Patients with HR+/HER2-metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Abstract 2251: Tumor Tissue Gene Expression in Association with Survival of Triple-Negative Breast Cancer

Prognostic Impact Of Mutation Profiling In Chinese Patients With Colorectal Liver Metastases.

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.

Abstract P6-07-36: A Prognostic Model for Triple-Negative Breast Cancer Patients Based on Node Status, Cathpesin-D and Ki-67

Clinical Factors Associated with Comprehensive Genomic Variation Profiling of Cervical Cancer.